Framingham Project/Levy View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2008-2008

FUNDING AMOUNT

1127838 USD

ABSTRACT

This year the NHLBI CPS team has been heavily invested in research related to SHARe (SNP Health Association Resource), and in planning for the SABRe CVD Initiative (Systems Approach to Biomarker Research in Cardiovascular Disease). I. Dr. Levy Much of Dr. Levy'd personal scientific effort in 2008 has been devoted to two efforts: a) hypertension genetics and b) biomarker research. A) Dr. Levy is leading Framingham efforts in the area of hypertension genetics. This effort comprises 3 elements: i) Leader of the SHARe Blood Pressure Working Group, ii) Leader of the CARe Blood Pressure Working Group, and iii) Resequencing projects directed at hypertension candidate genes. In conjunction with SHARe, Dr. Levy hasestablished a consortium with investigators from Framingham, ARIC, Rotterdam, CHS, and AGES. Preliminary blood pressure GWAS results are available from 3 of those studies and we are in the process of completing a meta-analysis of results across all 5 participating observational studies. We successfully identified genomewide significant associations with hypertension, our primary publication was submitted to Nature Genetics and it sheds light on the genetic underpinnings of hypertension. Similarly, as leader of the CARe Blood Pressure Working Group, we will be analyzing 2500 cardiovascular candidate genes in relation to blood pressure. Third, Dr. Levy is co-PI (with Chris Newton-Cheh) of a resequencing study that will characterize rare variants in 23 BP candidate genes. We are in the process of genotyping about 250 variants (mostly missense) in these genes that are differentially present at the low or high extremes of blood pressure. We expect to complete this genotyping in 7000 Framingham participants in late 2008 and should have results in hand in early 2009. B) Much of Dr. Levy's effort in 2008 has been devoted to planning for the SABRe CVD Initiative. We are nearing finalization of a CRADA to conduct state-of-the-art discovery metabolomics and proteomics of atherosclerosis and of metabolic syndrome. We also are nearing the start of a feasibility study of gene expression profiling in 3 sources of WBC-derived RNA from Framingham participants that will be conducted in collaboration with the NHLBI Core Microarray Lab. If technical feasibility can be demonstrated for one or more RNA sources, we plan to move forward with a large-scale study of gene expression in 7000 Framingham individuals. When this resource is combined with the SHARe database, we will be able to catalog genetic contributions to gene expression and the relations of common genetic variation and gene expression to disease phenotypes. I have met with David Lipman and Jim Ostell to plan for NCBI to create a resource of gene expression data and to make this accessible to the outside scientific community in a manner similar to the SHARe resource. II. Dr. Fox Dr. Fox's scientific focus has been on research in the areas of metabolic disorders (obesity and diabetes) and kidney disease. A) In the area of obesity, Dr. Fox successfully mentored several post-doctoral fellows to create several CT fat datasets related to pericardial fat, fatty liver, and peri-aortic fat. These have resulted in several manuscripts that are currently being revised. Dr. Fox led the CHARGe obesity working group, which is an international consortium. They are putting our first paper together now. B) In the area of diabetes, Dr. Fox mentored Sarah Rosner (IRTA fellow) in a study of temporal trends in diabetes-related mortality, which resulted in a travel award at CVD Epidemiology meeting. Sarah also is submitted 2 CVD epi abstracts for 2009. Dr. Fox also participated in several glycemic traits related projects in terms of candidate gene studies and genome-wide association. 3) Kidney disease research efforts included mentoring of Meredith Foster (post-bac fellow) through several obesity and CKD papers, and the collection of a fatty kidney dataset for her doctoral dissertation at the Harvard School of Public Health. Dr. Fox also successfully collaborated with the ARIC study for 1.5 years for CKD genetics, which has resulted in 2 collaborative publications. In the CHARGe kidney disease working group, Dr. fox led an international consortium to study the genetics of renal disease and related traits. This has resulted in one paper in press at the Lancet exploring the genetics of uric acid and gout. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=7735052

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2206", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "1127838"
    }, 
    "description": "This year the NHLBI CPS team has been heavily invested in research related to SHARe (SNP Health Association Resource), and in planning for the SABRe CVD Initiative (Systems Approach to Biomarker Research in Cardiovascular Disease). I. Dr. Levy Much of Dr. Levy'd personal scientific effort in 2008 has been devoted to two efforts: a) hypertension genetics and b) biomarker research. A) Dr. Levy is leading Framingham efforts in the area of hypertension genetics. This effort comprises 3 elements: i) Leader of the SHARe Blood Pressure Working Group, ii) Leader of the CARe Blood Pressure Working Group, and iii) Resequencing projects directed at hypertension candidate genes. In conjunction with SHARe, Dr. Levy hasestablished a consortium with investigators from Framingham, ARIC, Rotterdam, CHS, and AGES. Preliminary blood pressure GWAS results are available from 3 of those studies and we are in the process of completing a meta-analysis of results across all 5 participating observational studies. We successfully identified genomewide significant associations with hypertension, our primary publication was submitted to Nature Genetics and it sheds light on the genetic underpinnings of hypertension. Similarly, as leader of the CARe Blood Pressure Working Group, we will be analyzing 2500 cardiovascular candidate genes in relation to blood pressure. Third, Dr. Levy is co-PI (with Chris Newton-Cheh) of a resequencing study that will characterize rare variants in 23 BP candidate genes. We are in the process of genotyping about 250 variants (mostly missense) in these genes that are differentially present at the low or high extremes of blood pressure. We expect to complete this genotyping in 7000 Framingham participants in late 2008 and should have results in hand in early 2009. B) Much of Dr. Levy's effort in 2008 has been devoted to planning for the SABRe CVD Initiative. We are nearing finalization of a CRADA to conduct state-of-the-art discovery metabolomics and proteomics of atherosclerosis and of metabolic syndrome. We also are nearing the start of a feasibility study of gene expression profiling in 3 sources of WBC-derived RNA from Framingham participants that will be conducted in collaboration with the NHLBI Core Microarray Lab. If technical feasibility can be demonstrated for one or more RNA sources, we plan to move forward with a large-scale study of gene expression in 7000 Framingham individuals. When this resource is combined with the SHARe database, we will be able to catalog genetic contributions to gene expression and the relations of common genetic variation and gene expression to disease phenotypes. I have met with David Lipman and Jim Ostell to plan for NCBI to create a resource of gene expression data and to make this accessible to the outside scientific community in a manner similar to the SHARe resource. II. Dr. Fox Dr. Fox's scientific focus has been on research in the areas of metabolic disorders (obesity and diabetes) and kidney disease. A) In the area of obesity, Dr. Fox successfully mentored several post-doctoral fellows to create several CT fat datasets related to pericardial fat, fatty liver, and peri-aortic fat. These have resulted in several manuscripts that are currently being revised. Dr. Fox led the CHARGe obesity working group, which is an international consortium. They are putting our first paper together now. B) In the area of diabetes, Dr. Fox mentored Sarah Rosner (IRTA fellow) in a study of temporal trends in diabetes-related mortality, which resulted in a travel award at CVD Epidemiology meeting. Sarah also is submitted 2 CVD epi abstracts for 2009. Dr. Fox also participated in several glycemic traits related projects in terms of candidate gene studies and genome-wide association. 3) Kidney disease research efforts included mentoring of Meredith Foster (post-bac fellow) through several obesity and CKD papers, and the collection of a fatty kidney dataset for her doctoral dissertation at the Harvard School of Public Health. Dr. Fox also successfully collaborated with the ARIC study for 1.5 years for CKD genetics, which has resulted in 2 collaborative publications. In the CHARGe kidney disease working group, Dr. fox led an international consortium to study the genetics of renal disease and related traits. This has resulted in one paper in press at the Lancet exploring the genetics of uric acid and gout.", 
    "endDate": "2008-12-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.279885.9", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2720189", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2720189"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "Z01HL006001"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "expression", 
      "metabolic syndrome", 
      "process", 
      "primary publications", 
      "hypertension", 
      "third", 
      "significant association", 
      "ARIC", 
      "meta-analysis", 
      "related traits", 
      "CVD epi", 
      "Framingham Project/Levy", 
      "paper", 
      "share", 
      "efforts", 
      "mortality", 
      "CHARGe obesity", 
      "art discovery metabolomics", 
      "Rotterdam", 
      "Dr. Levy", 
      "proteomics", 
      "kidney disease", 
      "Co-Pi", 
      "BP candidate genes", 
      "II", 
      "obesity", 
      "missense", 
      "conjunction", 
      "variants", 
      "gene expression", 
      "Dr. Fox", 
      "manner", 
      "leaders", 
      "public health", 
      "ARIC study", 
      "outside scientific community", 
      "Nature Genetics", 
      "Framingham participants", 
      "light", 
      "hand", 
      "atherosclerosis", 
      "large-scale studies", 
      "elements", 
      "Systems Approach", 
      "study", 
      "diabetes", 
      "results", 
      "phenotype", 
      "common genetic variation", 
      "peri-aortic fat", 
      "CKD genetics", 
      "Kidney disease research efforts", 
      "SNP Health Association Resource", 
      "Framingham individuals", 
      "Preliminary blood pressure GWAS results", 
      "several post-doctoral fellows", 
      "CVD Epidemiology meeting", 
      "several obesity", 
      "share resources", 
      "Framingham", 
      "genomewide", 
      "gout", 
      "renal disease", 
      "consortium", 
      "years", 
      "pericardial fat", 
      "source", 
      "I. Dr. Levy Much", 
      "research", 
      "metabolic disorders", 
      "CHARGe kidney disease", 
      "SHARE database", 
      "groups", 
      "CRADA", 
      "genetic contribution", 
      "collaboration", 
      "NCBI", 
      "Framingham efforts", 
      "NHLBI Core Microarray Lab", 
      "start", 
      "Meredith Foster", 
      "cardiovascular candidate genes", 
      "more RNA sources", 
      "Dr. Levy'd personal scientific effort", 
      "doctoral dissertation", 
      "hypertension candidate genes", 
      "collaborative publications", 
      "genes", 
      "planning", 
      "several manuscripts", 
      "genome-wide association", 
      "travel awards", 
      "SHARe Blood Pressure Working Group", 
      "Lancet", 
      "first paper", 
      "temporal trends", 
      "Jim Ostell", 
      "Sarah", 
      "observational study", 
      "IRTA fellow", 
      "fatty kidney dataset", 
      "collection", 
      "finalization", 
      "candidate gene studies", 
      "Dr. Levy's effort", 
      "SABRe CVD Initiative", 
      "Chris Newton-Cheh", 
      "genetic underpinnings", 
      "post-bac fellow", 
      "David Lipman", 
      "area", 
      "terms", 
      "Harvard School", 
      "biomarker research", 
      "gene expression data", 
      "resources", 
      "CARe Blood Pressure Working Group", 
      "CHS", 
      "press", 
      "cardiovascular disease", 
      "Ages", 
      "relation", 
      "NHLBI CPS team", 
      "feasibility study", 
      "fatty liver", 
      "international consortium", 
      "project", 
      "hypertension genetics", 
      "high extremes", 
      "blood pressure", 
      "rare variants", 
      "resequencing study", 
      "RNA", 
      "CKD papers", 
      "several CT fat datasets", 
      "genetics", 
      "investigators", 
      "several glycemic traits", 
      "mentoring", 
      "uric acid", 
      "WBC", 
      "state", 
      "Sarah Rosner", 
      "technical feasibility", 
      "Dr. Fox Dr. Fox's scientific focus"
    ], 
    "name": "Framingham Project/Levy", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.279885.9", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.279885.9", 
          "name": "HEART, LUNG, AND BLOOD INSTITUTE", 
          "type": "Organization"
        }, 
        "familyName": "LEVY", 
        "givenName": "DANIEL", 
        "id": "sg:person.01302706715.35", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01302706715.35", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2720189"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_21.xml.gz", 
    "startDate": "2008-01-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=7735052"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2720189'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2720189'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2720189'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2720189'


 

This table displays all metadata directly associated to this object as RDF triples.

188 TRIPLES      19 PREDICATES      165 URIs      158 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2720189 schema:about anzsrc-for:2206
2 schema:amount N7e7f00754a544ee39a5b71eb461c3141
3 schema:description This year the NHLBI CPS team has been heavily invested in research related to SHARe (SNP Health Association Resource), and in planning for the SABRe CVD Initiative (Systems Approach to Biomarker Research in Cardiovascular Disease). I. Dr. Levy Much of Dr. Levy'd personal scientific effort in 2008 has been devoted to two efforts: a) hypertension genetics and b) biomarker research. A) Dr. Levy is leading Framingham efforts in the area of hypertension genetics. This effort comprises 3 elements: i) Leader of the SHARe Blood Pressure Working Group, ii) Leader of the CARe Blood Pressure Working Group, and iii) Resequencing projects directed at hypertension candidate genes. In conjunction with SHARe, Dr. Levy hasestablished a consortium with investigators from Framingham, ARIC, Rotterdam, CHS, and AGES. Preliminary blood pressure GWAS results are available from 3 of those studies and we are in the process of completing a meta-analysis of results across all 5 participating observational studies. We successfully identified genomewide significant associations with hypertension, our primary publication was submitted to Nature Genetics and it sheds light on the genetic underpinnings of hypertension. Similarly, as leader of the CARe Blood Pressure Working Group, we will be analyzing 2500 cardiovascular candidate genes in relation to blood pressure. Third, Dr. Levy is co-PI (with Chris Newton-Cheh) of a resequencing study that will characterize rare variants in 23 BP candidate genes. We are in the process of genotyping about 250 variants (mostly missense) in these genes that are differentially present at the low or high extremes of blood pressure. We expect to complete this genotyping in 7000 Framingham participants in late 2008 and should have results in hand in early 2009. B) Much of Dr. Levy's effort in 2008 has been devoted to planning for the SABRe CVD Initiative. We are nearing finalization of a CRADA to conduct state-of-the-art discovery metabolomics and proteomics of atherosclerosis and of metabolic syndrome. We also are nearing the start of a feasibility study of gene expression profiling in 3 sources of WBC-derived RNA from Framingham participants that will be conducted in collaboration with the NHLBI Core Microarray Lab. If technical feasibility can be demonstrated for one or more RNA sources, we plan to move forward with a large-scale study of gene expression in 7000 Framingham individuals. When this resource is combined with the SHARe database, we will be able to catalog genetic contributions to gene expression and the relations of common genetic variation and gene expression to disease phenotypes. I have met with David Lipman and Jim Ostell to plan for NCBI to create a resource of gene expression data and to make this accessible to the outside scientific community in a manner similar to the SHARe resource. II. Dr. Fox Dr. Fox's scientific focus has been on research in the areas of metabolic disorders (obesity and diabetes) and kidney disease. A) In the area of obesity, Dr. Fox successfully mentored several post-doctoral fellows to create several CT fat datasets related to pericardial fat, fatty liver, and peri-aortic fat. These have resulted in several manuscripts that are currently being revised. Dr. Fox led the CHARGe obesity working group, which is an international consortium. They are putting our first paper together now. B) In the area of diabetes, Dr. Fox mentored Sarah Rosner (IRTA fellow) in a study of temporal trends in diabetes-related mortality, which resulted in a travel award at CVD Epidemiology meeting. Sarah also is submitted 2 CVD epi abstracts for 2009. Dr. Fox also participated in several glycemic traits related projects in terms of candidate gene studies and genome-wide association. 3) Kidney disease research efforts included mentoring of Meredith Foster (post-bac fellow) through several obesity and CKD papers, and the collection of a fatty kidney dataset for her doctoral dissertation at the Harvard School of Public Health. Dr. Fox also successfully collaborated with the ARIC study for 1.5 years for CKD genetics, which has resulted in 2 collaborative publications. In the CHARGe kidney disease working group, Dr. fox led an international consortium to study the genetics of renal disease and related traits. This has resulted in one paper in press at the Lancet exploring the genetics of uric acid and gout.
4 schema:endDate 2008-12-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.279885.9
6 schema:identifier N599dd33407c544c5912feb511998f9c9
7 N758b1289f53d4eb19dad83c4d4b98362
8 schema:inLanguage en
9 schema:keywords ARIC
10 ARIC study
11 Ages
12 BP candidate genes
13 CARe Blood Pressure Working Group
14 CHARGe kidney disease
15 CHARGe obesity
16 CHS
17 CKD genetics
18 CKD papers
19 CRADA
20 CVD Epidemiology meeting
21 CVD epi
22 Chris Newton-Cheh
23 Co-Pi
24 David Lipman
25 Dr. Fox
26 Dr. Fox Dr. Fox's scientific focus
27 Dr. Levy
28 Dr. Levy'd personal scientific effort
29 Dr. Levy's effort
30 Framingham
31 Framingham Project/Levy
32 Framingham efforts
33 Framingham individuals
34 Framingham participants
35 Harvard School
36 I. Dr. Levy Much
37 II
38 IRTA fellow
39 Jim Ostell
40 Kidney disease research efforts
41 Lancet
42 Meredith Foster
43 NCBI
44 NHLBI CPS team
45 NHLBI Core Microarray Lab
46 Nature Genetics
47 Preliminary blood pressure GWAS results
48 RNA
49 Rotterdam
50 SABRe CVD Initiative
51 SHARE database
52 SHARe Blood Pressure Working Group
53 SNP Health Association Resource
54 Sarah
55 Sarah Rosner
56 Systems Approach
57 WBC
58 area
59 art discovery metabolomics
60 atherosclerosis
61 biomarker research
62 blood pressure
63 candidate gene studies
64 cardiovascular candidate genes
65 cardiovascular disease
66 collaboration
67 collaborative publications
68 collection
69 common genetic variation
70 conjunction
71 consortium
72 diabetes
73 doctoral dissertation
74 efforts
75 elements
76 expression
77 fatty kidney dataset
78 fatty liver
79 feasibility study
80 finalization
81 first paper
82 gene expression
83 gene expression data
84 genes
85 genetic contribution
86 genetic underpinnings
87 genetics
88 genome-wide association
89 genomewide
90 gout
91 groups
92 hand
93 high extremes
94 hypertension
95 hypertension candidate genes
96 hypertension genetics
97 international consortium
98 investigators
99 kidney disease
100 large-scale studies
101 leaders
102 light
103 manner
104 mentoring
105 meta-analysis
106 metabolic disorders
107 metabolic syndrome
108 missense
109 more RNA sources
110 mortality
111 obesity
112 observational study
113 outside scientific community
114 paper
115 peri-aortic fat
116 pericardial fat
117 phenotype
118 planning
119 post-bac fellow
120 press
121 primary publications
122 process
123 project
124 proteomics
125 public health
126 rare variants
127 related traits
128 relation
129 renal disease
130 research
131 resequencing study
132 resources
133 results
134 several CT fat datasets
135 several glycemic traits
136 several manuscripts
137 several obesity
138 several post-doctoral fellows
139 share
140 share resources
141 significant association
142 source
143 start
144 state
145 study
146 technical feasibility
147 temporal trends
148 terms
149 third
150 travel awards
151 uric acid
152 variants
153 years
154 schema:name Framingham Project/Levy
155 schema:recipient N68a3dfb925f647a98f50887e3f262596
156 sg:person.01302706715.35
157 https://www.grid.ac/institutes/grid.279885.9
158 schema:sameAs https://app.dimensions.ai/details/grant/grant.2720189
159 schema:sdDatePublished 2019-03-07T12:09
160 schema:sdLicense https://scigraph.springernature.com/explorer/license/
161 schema:sdPublisher Nb6e857df8a1e46fdaa6e947a6d8582ff
162 schema:startDate 2008-01-01T00:00:00Z
163 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=7735052
164 sgo:license sg:explorer/license/
165 sgo:sdDataset grants
166 rdf:type schema:MonetaryGrant
167 N599dd33407c544c5912feb511998f9c9 schema:name nih_id
168 schema:value Z01HL006001
169 rdf:type schema:PropertyValue
170 N68a3dfb925f647a98f50887e3f262596 schema:member sg:person.01302706715.35
171 schema:roleName PI
172 rdf:type schema:Role
173 N758b1289f53d4eb19dad83c4d4b98362 schema:name dimensions_id
174 schema:value 2720189
175 rdf:type schema:PropertyValue
176 N7e7f00754a544ee39a5b71eb461c3141 schema:currency USD
177 schema:value 1127838
178 rdf:type schema:MonetaryAmount
179 Nb6e857df8a1e46fdaa6e947a6d8582ff schema:name Springer Nature - SN SciGraph project
180 rdf:type schema:Organization
181 anzsrc-for:2206 schema:inDefinedTermSet anzsrc-for:
182 rdf:type schema:DefinedTerm
183 sg:person.01302706715.35 schema:affiliation https://www.grid.ac/institutes/grid.279885.9
184 schema:familyName LEVY
185 schema:givenName DANIEL
186 rdf:type schema:Person
187 https://www.grid.ac/institutes/grid.279885.9 schema:name HEART, LUNG, AND BLOOD INSTITUTE
188 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...